Skip to content

Observation on the effect of bupivacaine liposomes used in cryptonerve and IPACK block combined with multimodal analgesia in total knee arthroplasty

Observation on the effect of bupivacaine liposomes used in cryptonerve and IPACK block combined with multimodal analgesia in total knee arthroplasty

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087410
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee replacement

Interventions

Bupivacaine group:0.25% bupivacaine 100mg (40ml) was divided into two groups of 20ml liquid. Ultrasound-guided nerve block was performed 10min before anesthesia. Ultrasound-guided cryptographic nerve

Sponsors

The Northern Theater Command General Hospital of the People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Primary unilateral total knee arthroplasty was performed ?ASA grade I-III

Exclusion criteria

Exclusion criteria: ? Emergency surgery; ? Combined with uncontrolled hypertension, diabetes, etc.; ? Have a history of neurological diseases such as stroke and epilepsy; Combined with serious liver and kidney function damage, heart failure, malignant tumor and other serious diseases; (5) Long-term use of opioids; ? Infection at the nerve block site; ? Patients can not cooperate with research, such as: language understanding, mental illness, etc Those who are allergic to the drugs used in this study; ? Participated in EXPAREL study before ? Currently pregnant, breastfeeding or trying to become pregnant Diabetic neuropathy, coagulation or bleeding disorders, severe peripheral vascular diseases, renal insufficiency, liver dysfunction, or other contraindications ? participated in other clinical trials within 3 months prior to study inclusion

Design outcomes

Primary

MeasureTime frame
Visual analogue VAS was used ;Area under the NRS pain intensity curve ;total number of compressions within 72h;

Secondary

MeasureTime frame
Time of first compression of the analgesic pump;Postoperative pain scoresVAS;Duration of first opioid (oxycodone) use, total use, and remedial analgesia rate;Total opioid consumption;The first straight leg elevation time, the first time to get out of bed, the first walking distance, and the postoperative hospitalization time;Incidence of falls;Incidence of toxicity in cardiovascular and central nervous system disorders;Incidence of neurological toxicity;Motor ability recovery;

Countries

China

Contacts

Public ContactYugang DIAO

The Northern Theater Command General Hospital of the People's Liberation Army

diao72@163.com+86 153 0988 1160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026